Reports
Independent Review of Executive Compensation: Yellow Corporation
The objective of this audit is to determine whether Yellow, and its affiliates, complied with executive compensation limits under Section 12.05 of its Loan and Guarantee Agreement with the U.S. Department of the Treasury.
Compilation of Lessons Learned Report
The objective of the report is to compile SIGPR's audit products as well as lessons learned related to SIGPR's budget, jurisdiction, and hiring authority.
Audit of Risk Factor Mitigation in MSLP Loans
The objective of this review is to develop other MSLP audit ideas derived from our data analytics platform and risk assessment.
Independent Review of Direct Loan Recipient: Map Large Inc.
The objective of the audit is to determine if Map Large follows the terms and conditions of its direct loan agreement.
Audit of the Effects the MSLP’s Loan Losses Have on Treasury’s Investment
The Federal Reserve Bank of Boston manages the Main Street Lending Program (MSLP) through a Special Purpose Vehicle, which is backed by a $16.6 billion equity investment by Treasury. SIGPR will issue cyclical interim reports to Treasury on the information gathered from the various banks that participate in the MSLP.
Disaster Preparedness of Federal Agencies
HUD OIG will summarize the conclusions/findings and recommendations reported by seven participating OIGs and the General Accountability Office related to natural disaster preparedness. Our objective is to inform Federal agencies and the OIG community of the reported conclusions/findings and recommendations regarding preparing for and responding to natural disasters.
Audit of the Main Street Lending Program
The Office of the Special Inspector General for Pandemic Recovery is evaluating funds that were allocated to the Federal Reserve System’s Main Street Lending Program (MSLP), which had 319 lenders and 1,830 borrowers participating in loans totaling more than $17 billion. The objectives of the audit are to 1) assess the process used by banks to issue loans under the MSLP program; 2) evaluate the process used by the Federal Reserve’s Special Purpose Vehicle to purchase the loans; 3) determine vulnerabilities based on a risk-based analysis; and 4) identify specific areas that warrant further audit work.
Audit of Health Resources and Services Administration's COVID-19 Supplemental Grant Funding for Health Centers
The Health Resources and Services Administration (HRSA) awarded nearly $2 billion in supplemental grant funding to 1,387 health centers nationwide in fiscal year (FY) 2020 to respond to the COVID-19 public health emergency. The funding was intended to support the health centers' activities related to the detection, prevention, diagnosis, and treatment of COVID-19, including maintaining or increasing health center capacity and staffing levels during the pandemic, and expanding COVID-19 testing. The performance period for each of these one-time supplemental grant awards, which HRSA began awarding in March 2020, is 12 months. Health centers were permitted to charge to their awards pre-award costs in order to support expenses related to the COVID-19 public health emergency dating back to January 20, 2020. We will determine whether health centers used their HRSA COVID-19 supplemental grant funding in accordance with Federal requirements and grant terms.
Yearend Review of Opioid Use in Medicare Part D in 2020
Identifying patients who are at-risk of overdose or abuse is key to addressing this crisis. The COVID-19 pandemic has made this need even more pressing. The National Institutes of Health recently warned that individuals with opioiduse disorder could be particularly hard hit by COVID-19, which is a respiratory virus that attacks the lungs. Respiratory disease is known to increase mortality risks among people taking opioids. This data brief would provide information on opioid utilization among beneficiaries enrolled in Medicare Part D in 2020.
Awardee Challenges in Implementing COVID_19 Vaccination Program
CDC Immunization and Vaccines for Children Cooperative Agreement awardees, which are typically State and large metropolitan area public health departments, plan for and oversee the vaccine distribution and administration process. Stakeholders have acknowledged challenges early in Phase 1 distribution and dispensing, and note that these challenges will likely span all three phases identified in the CDC's COVID-19 Vaccine Playbook. We will interview all awardees to identify the reported challenges they are facing while distributing and dispensing vaccines. We will also ask awardees about effective strategies to mitigate those challenges, new challenges they anticipate, and how HHS can best support them in distributing and dispensing COVID-19 vaccines. In doing so, this review will provide HHS with timely and actionable information to address challenges associated with the COVID-19 vaccination efforts.